Dexcom Inc（DXCM）股票分析DXCMDexcom Inc

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Dexcom Inc (DXCM) is currently priced at $77.94, which is below several analyst price targets, including a target of $115 from Barclays. However, the stock has shown a significant 5-day decline of 9.41% and an RSI of 20.891, indicating it is oversold. While there are positive catalysts such as strong revenue growth and a gross margin of 63.44%, the current market conditions and upcoming earnings report on October 29 create uncertainty. Therefore, it may be prudent to hold rather than buy at this moment, as the stock could face volatility in the short term.

18 analysts cover DXCM: 11 rate it Buy, 7 Hold and 0 Sell. The average price target is 82.54.